Glycyrrhizin treatment is associated with attenuation of lipopolysaccharide-induced acute lung injury by inhibiting cyclooxygenase-2 and inducible nitric oxide synthase expression. 2011

Yun-Feng Ni, and Jian-Ke Kuai, and Zi-Fan Lu, and Guo-Dong Yang, and Hai-Yan Fu, and Jian Wang, and Feng Tian, and Xiao-Long Yan, and Ya-Chao Zhao, and Yun-Jie Wang, and Tao Jiang
Department of Thoracic Surgery, Tangdu Hospital, The Fourth Military Medical University, Xi'an, China.

Glycyrrhizin (GL), a major active constituent of licorice root, has been attributed numerous pharmacologic effects, including anti-inflammatory, anti-viral, anti-tumor, and hepatoprotective activities. In this study, we investigated the anti-inflammatory effect of GL on lipopolysaccharide (LPS)-induced acute lung injury (ALI) in mice. ALI was induced in Balb/c mice by intratracheal instillation of LPS (1 mg/kg). Before 1 h of LPS administration, the mice received intraperitoneal injection of GL at varied doses (10, 25, and 50 mg/kg). The severity of pulmonary injury was evaluated 12 h after LPS administration. GL pretreatment led to significant attenuation of LPS induced evident lung histopathologic changes, alveolar hemorrhage, and neutrophil infiltration with evidence of reduced myeloperoxidase (MPO) activity. The lung wet/dry weight ratios, as an index of lung edema, were markedly reduced by GL pretreatment. The concentrations of pro-inflammatory cytokines interleukin (IL)-1β and tumor necrosis factor (TNF)-α were elevated in bronchoalveolar lavage fluid (BALF) after LPS administration, which were significantly inhibited by GL pretreatment. GL pretreatment also reduced the concentrations of nitric oxide (NO) in lung tissues. Furthermore, the expression of cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) was suppressed by GL pretreatment. In conclusion, GL potently protected against LPS-induced ALI, and the protective effects of GL may attribute partly to the suppression of COX-2 and iNOS expression.

UI MeSH Term Description Entries
D008070 Lipopolysaccharides Lipid-containing polysaccharides which are endotoxins and important group-specific antigens. They are often derived from the cell wall of gram-negative bacteria and induce immunoglobulin secretion. The lipopolysaccharide molecule consists of three parts: LIPID A, core polysaccharide, and O-specific chains (O ANTIGENS). When derived from Escherichia coli, lipopolysaccharides serve as polyclonal B-cell mitogens commonly used in laboratory immunology. (From Dorland, 28th ed) Lipopolysaccharide,Lipoglycans
D008168 Lung Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood. Lungs
D008297 Male Males
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D009195 Peroxidase A hemeprotein from leukocytes. Deficiency of this enzyme leads to a hereditary disorder coupled with disseminated moniliasis. It catalyzes the conversion of a donor and peroxide to an oxidized donor and water. EC 1.11.1.7. Myeloperoxidase,Hemi-Myeloperoxidase,Hemi Myeloperoxidase
D009569 Nitric Oxide A free radical gas produced endogenously by a variety of mammalian cells, synthesized from ARGININE by NITRIC OXIDE SYNTHASE. Nitric oxide is one of the ENDOTHELIUM-DEPENDENT RELAXING FACTORS released by the vascular endothelium and mediates VASODILATION. It also inhibits platelet aggregation, induces disaggregation of aggregated platelets, and inhibits platelet adhesion to the vascular endothelium. Nitric oxide activates cytosolic GUANYLATE CYCLASE and thus elevates intracellular levels of CYCLIC GMP. Endogenous Nitrate Vasodilator,Mononitrogen Monoxide,Nitric Oxide, Endothelium-Derived,Nitrogen Monoxide,Endothelium-Derived Nitric Oxide,Monoxide, Mononitrogen,Monoxide, Nitrogen,Nitrate Vasodilator, Endogenous,Nitric Oxide, Endothelium Derived,Oxide, Nitric,Vasodilator, Endogenous Nitrate
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014409 Tumor Necrosis Factor-alpha Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS. Cachectin,TNF-alpha,Tumor Necrosis Factor Ligand Superfamily Member 2,Cachectin-Tumor Necrosis Factor,TNF Superfamily, Member 2,TNFalpha,Tumor Necrosis Factor,Cachectin Tumor Necrosis Factor,Tumor Necrosis Factor alpha
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus
D051546 Cyclooxygenase 2 An inducibly-expressed subtype of prostaglandin-endoperoxide synthase. It plays an important role in many cellular processes and INFLAMMATION. It is the target of COX2 INHIBITORS. COX-2 Prostaglandin Synthase,Cyclo-Oxygenase II,Cyclooxygenase-2,PGHS-2,PTGS2,Prostaglandin H Synthase-2,COX 2 Prostaglandin Synthase,Cyclo Oxygenase II,Prostaglandin H Synthase 2,Prostaglandin Synthase, COX-2,Synthase, COX-2 Prostaglandin

Related Publications

Yun-Feng Ni, and Jian-Ke Kuai, and Zi-Fan Lu, and Guo-Dong Yang, and Hai-Yan Fu, and Jian Wang, and Feng Tian, and Xiao-Long Yan, and Ya-Chao Zhao, and Yun-Jie Wang, and Tao Jiang
November 2014, European journal of pharmacology,
Yun-Feng Ni, and Jian-Ke Kuai, and Zi-Fan Lu, and Guo-Dong Yang, and Hai-Yan Fu, and Jian Wang, and Feng Tian, and Xiao-Long Yan, and Ya-Chao Zhao, and Yun-Jie Wang, and Tao Jiang
January 2009, Clinical hemorheology and microcirculation,
Yun-Feng Ni, and Jian-Ke Kuai, and Zi-Fan Lu, and Guo-Dong Yang, and Hai-Yan Fu, and Jian Wang, and Feng Tian, and Xiao-Long Yan, and Ya-Chao Zhao, and Yun-Jie Wang, and Tao Jiang
March 2008, Bioorganic & medicinal chemistry letters,
Yun-Feng Ni, and Jian-Ke Kuai, and Zi-Fan Lu, and Guo-Dong Yang, and Hai-Yan Fu, and Jian Wang, and Feng Tian, and Xiao-Long Yan, and Ya-Chao Zhao, and Yun-Jie Wang, and Tao Jiang
January 2005, FEMS immunology and medical microbiology,
Yun-Feng Ni, and Jian-Ke Kuai, and Zi-Fan Lu, and Guo-Dong Yang, and Hai-Yan Fu, and Jian Wang, and Feng Tian, and Xiao-Long Yan, and Ya-Chao Zhao, and Yun-Jie Wang, and Tao Jiang
June 2001, Biochemical pharmacology,
Yun-Feng Ni, and Jian-Ke Kuai, and Zi-Fan Lu, and Guo-Dong Yang, and Hai-Yan Fu, and Jian Wang, and Feng Tian, and Xiao-Long Yan, and Ya-Chao Zhao, and Yun-Jie Wang, and Tao Jiang
July 2006, Blood,
Yun-Feng Ni, and Jian-Ke Kuai, and Zi-Fan Lu, and Guo-Dong Yang, and Hai-Yan Fu, and Jian Wang, and Feng Tian, and Xiao-Long Yan, and Ya-Chao Zhao, and Yun-Jie Wang, and Tao Jiang
April 2012, Thrombosis research,
Yun-Feng Ni, and Jian-Ke Kuai, and Zi-Fan Lu, and Guo-Dong Yang, and Hai-Yan Fu, and Jian Wang, and Feng Tian, and Xiao-Long Yan, and Ya-Chao Zhao, and Yun-Jie Wang, and Tao Jiang
August 2003, American journal of respiratory and critical care medicine,
Yun-Feng Ni, and Jian-Ke Kuai, and Zi-Fan Lu, and Guo-Dong Yang, and Hai-Yan Fu, and Jian Wang, and Feng Tian, and Xiao-Long Yan, and Ya-Chao Zhao, and Yun-Jie Wang, and Tao Jiang
December 1998, American journal of respiratory and critical care medicine,
Yun-Feng Ni, and Jian-Ke Kuai, and Zi-Fan Lu, and Guo-Dong Yang, and Hai-Yan Fu, and Jian Wang, and Feng Tian, and Xiao-Long Yan, and Ya-Chao Zhao, and Yun-Jie Wang, and Tao Jiang
February 2008, Critical care medicine,
Copied contents to your clipboard!